DAMORA THERAPEUTICS, INC. Research and Development Expense
DAMORA THERAPEUTICS, INC. (DMRA) reported Research and Development Expense of $25.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $25.54M, a 1643.34% increase year-over-year.
- DAMORA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $23.78M, a 3406.93% increase year-over-year.
- DAMORA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $23.32M, a 2213.29% increase year-over-year.
- DAMORA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $1.42M, a 29.55% increase year-over-year.
- DAMORA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $26.88M, a 320.08% increase from fiscal 2024.
- DAMORA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $6.40M, a 73.08% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $23.77M, a 50.69% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $48.21M, a 25.25% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.54M 10-Q · filed 2026-08-10 | $49.32M 10-Q · filed 2026-08-10 | $72.64M derived: sum of 3 quarters · filed 2026-08-10 | $74.05M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $23.78M 10-Q · filed 2026-05-12 | $47.09M derived: sum of 2 quarters · filed 2026-05-12 | $48.51M derived: sum of 3 quarters · filed 2026-05-12 | $49.98M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $23.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $24.73M derived: sum of 2 quarters · filed 2026-03-19 | $26.20M derived: sum of 3 quarters · filed 2026-08-10 | $26.88M 10-K · filed 2026-03-19 |
| 2025-09-30 | $1.42M 10-Q · filed 2025-11-06 | $2.88M derived: sum of 2 quarters · filed 2026-08-10 | $3.56M 10-Q · filed 2025-11-06 | $4.57M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.47M 10-Q · filed 2026-08-10 | $2.14M 10-Q · filed 2026-08-10 | $3.15M derived: sum of 3 quarters · filed 2026-08-10 | $4.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $678.00K 10-Q · filed 2026-05-12 | $1.69M derived: sum of 2 quarters · filed 2026-05-12 | $2.78M derived: sum of 3 quarters · filed 2026-05-12 | $4.61M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.10M derived: sum of 2 quarters · filed 2026-03-19 | $3.94M derived: sum of 3 quarters · filed 2026-03-19 | $6.40M 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.09M 10-Q · filed 2025-11-06 | $2.93M derived: sum of 2 quarters · filed 2025-11-06 | $5.39M 10-Q · filed 2025-11-06 | $8.16M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.83M 10-Q · filed 2025-08-05 | $4.30M 10-Q · filed 2025-08-05 | $7.07M derived: sum of 3 quarters · filed 2025-08-05 | $9.62M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $2.46M 10-Q · filed 2025-05-08 | $5.23M derived: sum of 2 quarters · filed 2025-05-08 | $7.78M derived: sum of 3 quarters · filed 2025-05-08 | $15.87M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $5.32M derived: sum of 2 quarters · filed 2025-03-19 | $13.41M derived: sum of 3 quarters · filed 2025-03-19 | $23.77M 10-K · filed 2025-03-19 |
| 2023-09-30 | $2.55M 10-Q · filed 2024-11-01 | $10.64M derived: sum of 2 quarters · filed 2024-11-01 | $21.00M 10-Q · filed 2024-11-01 | $31.77M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $8.09M 10-Q · filed 2024-08-12 | $18.45M 10-Q · filed 2024-08-12 | $29.22M derived: sum of 3 quarters · filed 2024-08-12 | $39.72M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $10.36M 10-Q · filed 2024-04-29 | $21.13M derived: sum of 2 quarters · filed 2024-04-29 | $31.63M derived: sum of 3 quarters · filed 2024-04-29 | $45.33M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $21.26M derived: sum of 2 quarters · filed 2024-03-08 | $34.97M derived: sum of 3 quarters · filed 2024-03-08 | $48.21M 10-K · filed 2024-03-08 |
| 2022-09-30 | $10.49M 10-Q · filed 2023-11-06 | $24.20M derived: sum of 2 quarters · filed 2023-11-06 | $37.44M 10-Q · filed 2023-11-06 | $47.55M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $13.71M 10-Q · filed 2023-07-31 | $26.94M 10-Q · filed 2023-07-31 | $37.06M derived: sum of 3 quarters · filed 2023-07-31 | $46.80M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $13.23M 10-Q · filed 2023-04-28 | $23.35M derived: sum of 2 quarters · filed 2023-04-28 | $33.10M derived: sum of 3 quarters · filed 2023-04-28 | $41.73M derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $10.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $19.86M derived: sum of 2 quarters · filed 2023-03-09 | $28.50M derived: sum of 3 quarters · filed 2023-03-09 | $38.49M 10-K · filed 2023-03-09 |
| 2021-09-30 | $9.75M 10-Q · filed 2022-11-08 | $18.38M derived: sum of 2 quarters · filed 2022-11-08 | $28.37M 10-Q · filed 2022-11-08 | $36.13M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $8.63M 10-Q · filed 2022-07-29 | $18.63M 10-Q · filed 2022-07-29 | $26.38M derived: sum of 3 quarters · filed 2022-07-29 | $34.03M derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | $9.99M 10-Q · filed 2022-04-29 | $17.74M derived: sum of 2 quarters · filed 2022-04-29 | $25.39M derived: sum of 3 quarters · filed 2022-04-29 | $29.91M derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $15.40M derived: sum of 2 quarters · filed 2022-02-17 | $19.92M derived: sum of 3 quarters · filed 2022-02-17 | $24.63M 10-K · filed 2022-02-17 |
| 2020-09-30 | $7.65M 10-Q · filed 2021-11-04 | $12.17M derived: sum of 2 quarters · filed 2021-11-04 | $16.87M 10-Q · filed 2021-11-04 | $24.72M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $4.51M 10-Q · filed 2021-08-05 | $9.22M 10-Q · filed 2021-08-05 | $17.07M derived: sum of 3 quarters · filed 2021-08-05 | $20.74M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $4.71M 10-Q · filed 2021-05-04 | $12.55M derived: sum of 2 quarters · filed 2021-05-04 | $16.23M derived: sum of 3 quarters · filed 2021-05-04 | |
| 2019-12-31 | $7.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $11.52M derived: sum of 2 quarters · filed 2021-03-29 | $19.74M 10-K · filed 2021-03-29 | |
| 2019-09-30 | $3.67M 10-Q · filed 2020-12-11 | $11.89M 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |